Airway diseases
E-poster
Inhaled treatments for COPD: clinical trials and real-world studies
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Methods :
Public health, Pulmonary function testing, Epidemiology, General respiratory patient care
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
J. Hurst(London, United Kingdom)
COI
1
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial
K. Rabe(Kiel, Germany)
COI
2
Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial
G. Ferguson(Farmington Hills, United States)
COI
3
The association between health-related quality of life and COPD exacerbations measured by EQ-5D-5L in the ETHOS trial
D. Jackson(Cambridge, United Kingdom)
COI
4
Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial
5
Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study.
S. Tryfon(Panorama, Greece)
COI
6
Lung function and reported dyspnea in Greek COPD patients under treatment with fluticasone/salmeterol FDC via Elpenhaler device with or without cardiovascular comorbidity - AEOLOS study.
M. Bertoli(Pikermi, Greece)
COI
7
Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial
L. Bjermer(Lund, Sweden)
COI
8
Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD
H. Shafiek(Alexandria, Egypt)
COI
9
Are COPD prescription patterns aligned with guidelines? a population-based study
T. Bahremand(Vancouver, Canada)
COI
10
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
V. Neches(Tres Cantos, Spain)
COI
11
. . .
